Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial
- PMID: 2509103
- DOI: 10.1161/01.cir.80.5.1166
Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial
Abstract
In the Second Mt. Sinai-New York University Reperfusion Trial, in which change of ejection fraction was the primary end point, the following secondary end points were prospectively assessed by serial coronary angiography: patency of the infarct artery both before intervention and 10-14 days later, acute and delayed recanalization rates, presence or absence of collateral flow, and complication rates of acute interventional catheterization. We assigned 393 patients randomly to groups receiving acute cardiac catheterization and a double-blind intracoronary infusion of streptokinase (SK arm), both streptokinase and nitroglycerin (SK-NTG arm), nitroglycerin alone (NTG arm), or conventional therapy without acute catheterization (control arm). Prospective stratification was based on duration of infarct pain before randomization: group A, less than 2 hours; Group B, 2-12 hours. Baseline patency rates were comparable in patients studied within 6 hours (30%, 40 of 135) and those studied later (24%, 32 of 133). This finding refutes the hypothesis that spontaneous recanalization occurs frequently after 6 hours. The acute recanalization rates of the SK arm (60%, 40 of 67) and the SK-NTG arm (63%, 29 of 62) did not differ. During streptokinase infusion, more vessels recanalized in group A (81%, 22 of 27) than in group B (56%, 57 of 102) (p less than 0.01); this was due to a significant reduction of recanalization rates from 75% (48 of 64) to 45% (26 of 62) with treatment after 6 hours (p less than 0.01). Delayed recanalization, that is, patency at end point but not postintervention, was seen in 17% (17 of 100) of total occlusions treated with streptokinase. In group A, all total occlusions treated with streptokinase recanalized either acutely (20 of 22) or delayed (two of 22), whereas in group B, 23% (18 of 78) remained obstructed. The reocclusion rate in the SK arms was 17% (11 of 65). In the NTG arm, recanalization occurred during intervention in 4% (two of 47) and delayed in 45% (21 of 47). At end-point angiography, the patency rates of the NTG arm (62%, 41 of 66) and the control arm (58%, 36 of 62) were comparable; those of the SK arms were higher (75%, 105 of 140) (p less than 0.01). Total occlusion was associated with collateral flow in 33% (66 of 199) at baseline; the prevalence of collaterals did not increase with time to angiography, which indicates that they had developed before the index event.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary end point findings of the Second Mount Sinai-New York University Reperfusion Trial.J Am Coll Cardiol. 1989 Jul;14(1):58-64. doi: 10.1016/0735-1097(89)90054-5. J Am Coll Cardiol. 1989. PMID: 2500472 Clinical Trial.
-
Changes in left ventricular function after intracoronary streptokinase infusion in clinically evolving myocardial infarction.Am Heart J. 1981 Dec;102(6 Pt 2):1188-93. doi: 10.1016/0002-8703(81)90651-7. Am Heart J. 1981. PMID: 7315723
-
Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction.N Engl J Med. 1984 Dec 6;311(23):1457-63. doi: 10.1056/NEJM198412063112301. N Engl J Med. 1984. PMID: 6438504 Clinical Trial.
-
Thrombolytic therapy in acute myocardial infarction: review of clinical trials.Am J Cardiol. 1984 Dec 21;54(11):29E-31E. doi: 10.1016/s0002-9149(84)80310-0. Am J Cardiol. 1984. PMID: 6439024 Review.
-
Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction.Am J Cardiol. 1989 Jul 5;64(2):12A-17A; discussion 24A-26A. doi: 10.1016/0002-9149(89)90923-5. Am J Cardiol. 1989. PMID: 2662737 Review.
Cited by
-
Advances in thrombolytic therapy.Cardiovasc Drugs Ther. 1992 Apr;6(2):111-24. doi: 10.1007/BF00054557. Cardiovasc Drugs Ther. 1992. PMID: 1390321 Review.
-
Effect of Poloxamer 188 on Collateral Blood Flow, Myocardial Infarct Size, and Left Ventricular Function in a Canine Model of Prolonged (3-Hour) Coronary Occlusion and Reperfusion.J Thromb Thrombolysis. 1998 Jul;5(3):239-247. doi: 10.1023/A:1008848026759. J Thromb Thrombolysis. 1998. PMID: 10767120
-
Temporal patterns of blood flow and nitric oxide synthase expression affect macrophage accumulation and proliferation during collateral growth.J Angiogenes Res. 2010 Sep 16;2:18. doi: 10.1186/2040-2384-2-18. J Angiogenes Res. 2010. PMID: 20843382 Free PMC article.
-
Collateral Circulation in Chronic Total Occlusions – an interventional perspective.Curr Cardiol Rev. 2015 Nov 6;11(4):277-284. doi: 10.2174/1573403X11666150909112548. Curr Cardiol Rev. 2015. PMID: 26354508 Free PMC article.
-
Why Should Growth Hormone (GH) Be Considered a Promising Therapeutic Agent for Arteriogenesis? Insights from the GHAS Trial.Cells. 2020 Mar 27;9(4):807. doi: 10.3390/cells9040807. Cells. 2020. PMID: 32230747 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical